MedTrace Logo

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

NCT07497074 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-03-27

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.

Conditions

Interventions

DRUG

JSKN033

JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

DRUG

Platinum

JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

DRUG

Bevacizumab

JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-10-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07497074 on ClinicalTrials.gov